saf research semaglutide review Frontiers Cardiovascular outcomes of semaglutide and

Right now, GLP-1 medications are not approved for use during pregnancy

Murtaza N, Cheng AA, Brown CO, Meka DP, Hong S, Uy JA, El-Hajjar J, Pipko N, Unda BK, Schwanke B, Xing S, Thiruvahindrapuram B, Engchuan W, Trost B, Deneault E, Calderon de Anda F, Doble BW, Ellis J, Anagnostou E, Bader GD, Scherer SW, Lu Y, Singh KK (2022) Neuron-specific protein network mapping of Autism risk genes identifies shared biological mechanisms and disease-relevant pathologies

Seven additional Phase 3 readouts are expected throughout 2026, including studies evaluating maintenance dosing at 4 mg (in addition to the 9 mg and 12 mg doses already tested)

Early recognition through symptom tracking helps healthcare providers distinguish between normal adjustment effects and true gastroparesis, enabling timely intervention while preserving treatment benefits